Finding that the protein levels of p110β, but not p110α, were upregulated in most endometrial carcinoma cell lines, we then demonstrated the distinct contribution of p110α and p110β to cell survival, proliferation and signaling depending on the presence of PTEN and PIK3CA mutations, using selective pharmacological inhibitors. Here, PIK3CA is linked to endometrial carcinoma.